JP2000504579A5 - - Google Patents

Download PDF

Info

Publication number
JP2000504579A5
JP2000504579A5 JP1997528984A JP52898497A JP2000504579A5 JP 2000504579 A5 JP2000504579 A5 JP 2000504579A5 JP 1997528984 A JP1997528984 A JP 1997528984A JP 52898497 A JP52898497 A JP 52898497A JP 2000504579 A5 JP2000504579 A5 JP 2000504579A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1997528984A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000504579A (ja
Filing date
Publication date
Priority claimed from DE19605548A external-priority patent/DE19605548A1/de
Application filed filed Critical
Publication of JP2000504579A publication Critical patent/JP2000504579A/ja
Publication of JP2000504579A5 publication Critical patent/JP2000504579A5/ja
Abandoned legal-status Critical Current

Links

JP9528984A 1996-02-15 1997-02-13 高等真核細胞の形質移入のための組成物 Abandoned JP2000504579A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19605548.2 1996-02-15
DE19605548A DE19605548A1 (de) 1996-02-15 1996-02-15 Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
PCT/EP1997/000649 WO1997030170A1 (de) 1996-02-15 1997-02-13 Zusammensetzung für die transfektion höherer eukaryotischer zellen

Publications (2)

Publication Number Publication Date
JP2000504579A JP2000504579A (ja) 2000-04-18
JP2000504579A5 true JP2000504579A5 (enExample) 2004-11-18

Family

ID=7785445

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9528984A Abandoned JP2000504579A (ja) 1996-02-15 1997-02-13 高等真核細胞の形質移入のための組成物

Country Status (6)

Country Link
EP (1) EP0900281A1 (enExample)
JP (1) JP2000504579A (enExample)
CA (1) CA2246227A1 (enExample)
DE (1) DE19605548A1 (enExample)
MX (1) MX9805507A (enExample)
WO (1) WO1997030170A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766705B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation
FR2766706B1 (fr) * 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
GB9918670D0 (en) 1999-08-06 1999-10-13 Celltech Therapeutics Ltd Biological product
GB0120022D0 (en) * 2001-08-16 2001-10-10 Photobiotics Ltd Conjugate
HUE026646T2 (en) 2010-07-06 2016-07-28 Glaxosmithkline Biologicals Sa Preferred liposomes containing lipids of PKA value for delivery of RNA
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
PL2591114T3 (pl) 2010-07-06 2017-08-31 Glaxosmithkline Biologicals Sa Immunizacja dużych ssaków małymi dawkami rna
RS63329B1 (sr) 2010-08-31 2022-07-29 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
JP2014520806A (ja) 2011-07-06 2014-08-25 ノバルティス アーゲー Rna分子の送達のための有用なn:p比を有するリポソーム
KR101956751B1 (ko) 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 키메라 항원 수용체
WO2017024319A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
JP7045378B2 (ja) 2016-09-01 2022-03-31 キメラ・バイオエンジニアリング,インコーポレーテッド Gold最適化CAR T細胞
WO2018148440A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US20240216509A1 (en) 2018-05-07 2024-07-04 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
US20220143094A1 (en) 2019-04-19 2022-05-12 Chugai Seiyaku Kabushiki Kaisha Chimeric receptor that recognizes engineered site in antibody
KR20220017430A (ko) 2019-06-05 2022-02-11 추가이 세이야쿠 가부시키가이샤 항체 절단 부위 결합 분자
US20230322898A1 (en) 2020-07-31 2023-10-12 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising cell expressing chimeric receptor
CN116997654A (zh) 2021-03-17 2023-11-03 第一三共株式会社 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因
US20240366666A1 (en) 2021-04-08 2024-11-07 Phosphogam, Llc Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells
WO2024150525A1 (ja) 2023-01-12 2024-07-18 国立大学法人山口大学 抗ネコpd-1抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
FR2714830B1 (fr) * 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
US5928944A (en) * 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
IL115199A (en) * 1995-09-07 2005-05-17 Opperbas Holding Bv Composition comprising a polynucleic acid molecule in a liposome and method using said composition

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2001506266A5 (enExample)
JP2001504398A5 (enExample)
JP2000501324A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2000500874A5 (enExample)
JP2000514722A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000516811A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000513361A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)